Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

MIND diet for adults with multiple sclerosis

Official title: Randomized Controlled Trial of MIND Diet for Neuroprotection and Symptom Management in MS

Run by Icahn School of Medicine at Mount Sinai · NCT06992115 · Data updated 2026-11-12

This program will test whether following the MIND diet for one year helps brain health and reduces MS symptoms in adults with multiple sclerosis.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment100 (estimated)
SponsorIcahn School of Medicine at Mount Sinai
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedJuly 16, 2025
Main results expectedApril 30, 2029
Study endsApril 30, 2029
Registry record updatedOctober 2, 2026
Trial IDNCT06992115 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–70 with a diagnosis of multiple sclerosis, a baseline MIND diet score of 8 or less, and who are not pregnant are ideal candidates.

Probably not a fit

People with additional neurodegenerative or serious medical conditions, those planning pregnancy, or individuals already following a MIND-like diet (score above 8) may be unlikely to gain benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, stratified early phase II trial assigns adults with MS to either a one-year MIND dietary intervention with dietitian-led education and virtual support groups, or to a control arm that continues their usual diet and receives MS-related education unrelated to diet. Participants complete baseline, 6-month, and 12-month in-person visits with functional and cognitive testing, provide blood and stool samples, and complete online questionnaires. The intervention arm receives intensive virtual small-group meetings weekly for the first month and then monthly through month 12 to support MIND diet adherence. Randomization is stratified by MS phenotype and treatment type to balance groups.

Why it matters

Potential benefit: If successful, the MIND diet could offer a low-risk way to support brain health and reduce symptoms for people with MS.

How similar studies have gone: MIND and Mediterranean-style diets have shown cognitive and neuroprotective signals in aging and dementia research, but randomized evidence in MS is limited, making this a relatively novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Ages 18-70 years, inclusive
* MS diagnosis, on any treatment (including no treatment)
* MIND diet score of ≤9 at baseline

Exclusion Criteria:

* Diagnosis of an additional neurodegenerative disease (e.g. Alzheimer's) or other serious neurological condition (e.g. stroke)
* Current serious medical condition that could impact the ability to participate or influence study results (e.g. cancer, HIV)
* Pregnancy/planning during study period

Where it's running

  • Mount Sinai Hospital
    New York, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Ilana B Katz Sand, MD — Icahn School of Medicine at Mount Sinai
  • Study coordinator: Claire E Wigley, Bsc, BSPH
  • Email: claire.wigley@mssm.edu
  • Phone: (212) 241-3759

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.